QURE

uniQure shares closed at US$24.97 after a turbulent few years, and that mix of sharp swings and fresh clinical scrutiny now raises a straightforward question for investors about how the current market price lines up with the gene therapy specialist's book…

uniQure N.V. recently reported additional 36- and 48-month Phase I/II data for its Huntington’s disease gene therapy ifezuntirgene inilparvovec, showing continued slowing of disease progression versus matched external controls and supporting its previously…

uniQure (NasdaqGS:QURE) is back in focus after new 36- and 48-month data for its Huntington’s gene therapy, AMT-130, sparked sharp swings in the share price and renewed debate about the program.

uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential securities law violations. NEW YORK, Sept.

uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years.

Uniqure stock plummeted Tuesday on a disappointing four-year update for its experimental gene therapy in patients with Huntington's disease.

UniQure says it still sees a path to regulatory approval for the drug candidate, AMT-130, even as the experimental gene therapy for Huntington’s disease falls hort in a recent study.

uniQure’s Ifezuntirgene slowed disease progression by 80% on a measure combining movement, thinking and daily function.

uniQure N.V. (NASDAQ:QURE) submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for accelerated approval of ifezuntirgene inilparvovec, formerly AMT-130, in Huntington’s disease. uniQure N.V.

After a very large three year gain in uniQure’s share price, the stock now screens as overvalued on market multiples and carries a mixed overall value score rather than a clear bargain signal.

QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.

uniQure announced it had submitted a Biologics License Application to the FDA seeking accelerated approval of ifezuntirgene inilparvovec, or AMT-130, for Huntington’s disease.